Oxford BioTherapeutics, GSK Partner in $370M Cancer Drug Dea
UK biotech Oxford BioTherapeutics stands to gain $370 million under a new partnership with drug giant GlaxoSmithKline plc to discover, develop and commercialize therapeutic antibodies aimed at treating primary, metastatic and recurring forms of cancer. The deal represents OxFord’s transition from a discovery firm to a [...]